ARCHIVES

Critics of FDA misunderstand Bayesian analysis, statisticians say.

This article is from The Cancer Letter archive.

Vol. 31 No. 31 | August 5, 2005

Download PDF Visit The Full Archive

Related Articles

Centers’ Problems Get Increasing Attention From Staff, Advisors

August 20, 1976

New NCAB Task Force On Clinical Trials Is Attempt To Bring NCI, Groups Together

June 3, 1994

British Award 100,000 Pounds A Year To UICC

January 11, 1980

President’s Cancer Panel: NCI’s Approach “Paying Off,” Thompson Tells Cancer Panel

June 1, 2001

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

Congress Agrees On $1.989 Bil. FY92 NCI Budget, But Most Of Increase Not Available Till 1993

November 8, 1991